From the Editor

Aug 01, 2014
Pharmaceutical Executive
Pharm Exec's 2014 roster of emerging pharma leaders serves as a window on work in an industry that relies on human capital as the coinage of success, writes William Looney.
Jul 10, 2014
Pharmaceutical Executive
A surprising takeaway from the recent BIO Convention, writes William Looney, is the stark contrast between cooperative industry engagement and an unstable geopolitical order.
Jun 09, 2014
Pharmaceutical Executive
Finding the correct coordinates for big Pharma's endless cycle of re-positioning is just as important as a winning scientific hand, writes William Looney.
May 01, 2014
Pharmaceutical Executive
Recent deal making signals that the rehabilitation of big Pharma has entered a new phase aligned around a new strategic thesis, writes Pharm Exec Editor-in-Chief William Looney.
Apr 24, 2014
Pharmaceutical Executive
By Pharmaceutical Executive Editors
Four commercial line executives serve as our jury of peers on what's in store for the future of pharma, and discuss the changing criteria for market success, from drugs to consumer products to vaccines.
Apr 01, 2014
Pharmaceutical Executive
Three examples from Pharm Exec's coverage this month show that, in our industry, there are always two sides—at least—to every question.
Mar 01, 2014
Pharmaceutical Executive
Regardless of how you define it, partnership is also an institutional necessity as big Pharma adjusts to disruptive changes in the way health services are financed and delivered. A revolution in the making, where legislation combined with market forces as well as community and stakeholder advocacy are adding fresh momentum to a population-based approach to health practice. Population health focuses on a system built around three pillars of care: preventive care, primary care, and coordinated care, all driven by a single performance metric, which is value, as evidenced through quality and outcomes. Executing around this integrative model depends entirely on partnerships, especially with non-traditional players like the physician assistant.
Feb 01, 2014
Pharmaceutical Executive
By Pharmaceutical Executive Editors
Today, there is promise in new approaches that rely on the "other language of biology," using the human body's own circuitry of cells and nerves to induce precisely targeted therapeutic effects against a range of debilitating diseases.
Feb 01, 2014
Pharmaceutical Executive
By Pharmaceutical Executive Editors
For the first time, the spotlight shines on Russia's potential in biotechnology and pharma products
Jan 21, 2014
Pharmaceutical Executive
Pharm Exec begins its 34th year with a feature on Russia's ambitious plans to build a homegrown biopharma business. Back in 1980, the biotech industry did not exst. Drugs were still classified as chemicals, developed from the random screening of many thoughts.
native1_300x100
lorem ipsum